Turtlemint's IPO Nightmare Deepens on IRDAI Norms

is now trading around ₹79.52, extending a brutal slide that began when IRDAI proposed sweeping changes to insurance distribution economics. The trigger was a major regulatory proposal. IRDAI released a consultation paper, "Recalibrating Economics of Insurance Distribution," proposing a return to product-level commission caps roughly three years after such limits were removed, directly threatening commission income, Turtlemint's core revenue and customer-acquisition lever. The stock hit its lower circuit almost immediately after the news. It crashed 20% to ₹109.10 in a single session, which was also an all-time low at the time, taking its market cap down to roughly ₹3,213 crore. The damage has continued building. Together with PB Fintech, Turtlemint has lost a combined ₹35,705 crore in market cap over just three trading sessions since the news broke. This caps a rough IPO story overall. Turtlemint listed at ₹134.90, already an 11.25% discount to its ₹152 issue price, a weak debut for a still loss-making company, and the stock has since fallen well under half of that original issue price. A brief recovery attempt has since been wiped out. The stock had rallied to around ₹138 shortly before the IRDAI news broke, but that gain, and more, has now been completely erased. Fundamentals remain a work in progress. With a negative P/E and ROCE around -43% (1-year), the company isn't yet profitable, though it maintains a debt-free balance sheet and a healthy current ratio.